SHANGHAI & SUZHOU, China & CAMBRIDGE, MA, USA I January 09, 2025 I Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic ...
HANGZHOU, China I January 10, 2025 I Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative ...
Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The programs are based on Leyden Labs’ ...
Mean IL-1Ra expression reached and maintained target levels in synovial fluid throughout six-month follow-up period ...
The FDA and European Medicines Agency (EMA) have granted several key designations to nipocalimab including: U.S. FDA Fast Track designation in hemolytic disease of the fetus and newborn (HDFN) and ...
SHANGHAI, China I January 9, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significant milestone ...
BEIJING, China & PRAGUE, Czech Republic I January 09, 2025 I Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing ...
OTTAWA, Canada I January 9, 2025 I Esphera SynBio, a pre-clinical stage synthetic biology company, today announced a new project aimed at advancing ...
New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs ...
In both clinical trials, lixudebart demonstrated a favorable safety profile, both as a monotherapy and in combination with standard of care (n=51 active patients across the two trials). These findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback